Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Robert Matera & Muhammad Wasif Saif. (2017) New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies. Expert Opinion on Emerging Drugs 22:3, pages 223-233.
Read now
Read now
Giuseppe Aprile, Laura Ferrari, Chiara Cremolini, Francesca Bergamo, Caterina Fontanella, Francesca Battaglin, Karim Rihawi, Sara Lonardi, Fotios Loupakis & Mario Scartozzi. (2016) Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. Expert Review of Clinical Pharmacology 9:7, pages 877-885.
Read now
Read now
Aoife S Crawley & Richard J O’Kennedy. (2015) The need for effective pancreatic cancer detection and management: a biomarker-based strategy. Expert Review of Molecular Diagnostics 15:10, pages 1339-1353.
Read now
Read now
Articles from other publishers (9)
Sadra Samavarchi Tehrani, Fataneh Esmaeili, Moein Shirzad, Golnaz Goodarzi, Tooba Yousefi, Mahmood Maniati, Mortaza Taheri‐Anganeh & Amir Anushiravani. (2023) The critical role of circular RNAs in drug resistance in gastrointestinal cancers. Medical Oncology 40:4.
Crossref
Crossref
Mamoon Ur Rashid, Ishtiaq Hussain, Sundas Jehanzeb, Waqas Ullah, Saeed Ali, Akriti Gupta Jain, Ranjeet Kumar, Neelam Khetpal & Sarfraz Ahmad. 2019. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy
57
85
.
Rafał Kampa, Ilona Bednarek & Daniel Sypniewski. (2018) Monoclonal antibodies in regulation of signal transduction
of Epidermal Growth Factor Receptor (EGFR) pathway in cancer cells. Annales Academiae Medicae Silesiensis 72, pages 12-20.
Crossref
Crossref
Chih-Hsiung Hsieh, Chueh-Hsuan Lu, Wei-Ting Chen, Bo-Lun Ma & Chih-Yu Chao. (2017) Application of non-invasive low strength pulsed electric field to EGCG treatment synergistically enhanced the inhibition effect on PANC-1 cells. PLOS ONE 12:11, pages e0188885.
Crossref
Crossref
Cheng-Jeng Tai, Hang Wang, Chien-Kai Wang, Chen-Jei Tai, Ming-Te Huang, Chih-Hsiung Wu, Ray-Jade Chen, Li-Jen Kuo, Po-Lei Wei, Yu-Jia Chang, Chun-Chao Chang, Hung-Yi Chiou & Chang-Jer Wu. (2016) Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts. Clinical and Experimental Medicine 17:2, pages 141-150.
Crossref
Crossref
Qiangsheng Hu, Yi Qin, Bo Zhang, Chen Liang, Shunrong Ji, Si Shi, Wenyan Xu, Jinfeng Xiang, Dingkong Liang, Quanxing Ni, Xianjun Yu & Jin Xu. (2017) FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. Oncology Reports 38:4, pages 2069-2077.
Crossref
Crossref
Dietmar Zechner, Florian Bürtin, Ann-Christin Albert, Xianbin Zhang, Simone Kumstel, Maria Schönrogge, Josefine Graffunder, Hao-Yu Shih, Sarah Müller, Tobias Radecke, Robert Jaster & Brigitte Vollmar. (2016) Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin. Oncotarget 7:35, pages 56395-56407.
Crossref
Crossref
Jiezhong Chen, Kristin Kaley, Marie Carmel Garcon, Teresa Rodriguez & Muhammad Wasif Saif. (2015) A novel schedule of erlotinib/capecitabine (7/7) as salvage therapy in previously treated advanced pancreatic adenocarcinoma: a case series. Therapeutic Advances in Gastroenterology 9:2, pages 162-168.
Crossref
Crossref
Ashton A. Connor & Steven Gallinger. (2015) Hereditary Pancreatic Cancer Syndromes. Surgical Oncology Clinics of North America 24:4, pages 733-764.
Crossref
Crossref